Improved progression-free survival seen for amivantamab-lazertinib versus osimertinib as first-line treatment
MONDAY, July 1, 2024 (HealthDay News) — For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line treatment, according to a study published online June 26 in the New England Journal of Medicine.
Byoung C. Cho, M.D., Ph.D., from the Yonsei Cancer Center in Seoul, South Korea, and colleagues conducted a phase 3 trial involving patients with previously untreated EGFR-mutated, locally advanced or metastatic NSCLC randomly allocated to receive amivantamab-lazertinib (open-label), osimertinib (blinded), or lazertinib (blinded) in a 2:2:1 ratio (429, 429, and 216 patients, respectively).
The researchers found that the median progression-free survival was significantly longer in the amivantamab-lazertinib group than in the osimertinib group (23.7 versus 16.6 months; hazard ratio for disease progression or death, 0.70). An objective response was observed in 86 and 85 percent of patients in the amivantamab-lazertinib and osimertinib groups, respectively; among patients with a confirmed response, the median response duration was 25.8 and 16.8 months, respectively. The hazard ratio for death did not differ significantly in a planned interim overall survival analysis of amivantamab-lazertinib versus osimertinib. EGFR-related toxic effects were the predominant adverse events. The incidence of discontinuation of all agents due to treatment-related adverse events was 10 and 3 percent with amivantamab-lazertinib and osimertinib, respectively.
“We found that progression-free survival was significantly improved with amivantamab-lazertinib as compared with osimertinib as first-line treatment for EGFR-mutated advanced NSCLC,” the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Janssen, which manufactures amivantamab and lazertinib and funded the study.
Abstract/Full Text (subscription or payment may be required)
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL 
Gene Mutation Identified That Increases Lung Cancer Risk 
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors .jpg)
Recommendations Updated for Management of Anemia in CKD .jpg)
Mortality Lowest at Hemoglobin Concentrations Above WHO Thresholds 
More Advanced CKM Syndrome Linked to Worse Cardiovascular Health 
Preoperative IV Iron Beneficial for Patients With Anemia Undergoing Cardiac Surgery 
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML 
